$118.02
0.20% day before yesterday
NYSE, Jun 06, 10:10 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$118.02
+7.47 6.76% 1M
+16.03 15.72% 6M
+20.71 21.28% YTD
+11.89 11.20% 1Y
+36.92 45.52% 5Y
+21.99 22.90% 10Y
+71.40 153.13% 20Y
NYSE, Closing price Fri, Jun 06 2025
+0.23 0.20%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Market capitalization $224.53b
Enterprise Value $248.57b
P/E (TTM) P/E ratio 18.18
EV/FCF (TTM) EV/FCF 16.74
EV/Sales (TTM) EV/Sales 4.67
P/S ratio (TTM) P/S ratio 4.22
P/B ratio (TTM) P/B ratio 6.03
Dividend yield 3.38%
Last dividend (FY25) $3.99
Revenue growth (TTM) Revenue growth 11.57%
Revenue (TTM) Revenue $53.26b
EBIT (operating result TTM) EBIT $17.43b
Free Cash Flow (TTM) Free Cash Flow $14.85b
Cash position $7.14b
EPS (TTM) EPS $6.49
P/E forward 17.16
P/S forward 4.15
EV/Sales forward 4.59
Short interest 0.17%
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Novartis ADR forecast:

5x Buy
19%
15x Hold
58%
6x Sell
23%

Analyst Opinions

26 Analysts have issued a Novartis ADR forecast:

Buy
19%
Hold
58%
Sell
23%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
53,257 53,257
12% 12%
100%
- Direct Costs 12,948 12,948
3% 3%
24%
40,309 40,309
15% 15%
76%
- Selling and Administrative Expenses 12,781 12,781
3% 3%
24%
- Research and Development Expense 9,401 9,401
12% 12%
18%
17,672 17,672
55% 55%
33%
- Depreciation and Amortization 243 243
212% 212%
0%
EBIT (Operating Income) EBIT 17,429 17,429
54% 54%
33%
Net Profit 12,859 12,859
16% 16%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Neutral
The Motley Fool
one day ago
When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even worse than they already are.
Positive
Reuters
6 days ago
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered.
Positive
WSJ
6 days ago
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today